Sponsors / CRDF
CRDF

Cardiff Oncology

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
4Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate CancerNCT03414034Cardiff OncologyPhase 2Completed2023-10-16Actual
Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaNCT04752696Cardiff OncologyPhase 2Completed2024-12-24Actual
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) MutationNCT05593328Cardiff OncologyPhase 2Completed2024-12-09Actual
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationNCT06106308Cardiff OncologyPhase 2Active not recruiting2026-11Estimated

Latest recorded trial changes